Entera Bio Ltd. Debt/Equity

Debt/Equity of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Debt/Equity growth rates and interactive chart. The debt-to-equity (D/E) ratio is calculated by dividing a company's total interest-bearing liabilities by its shareholder equity. These numbers are available on the balance sheet of a company's financial statements. The ratio is used to evaluate a company's financial leverage. The debt/equity ratio can be compared to a company's historical average or to peers. A ratio above 1 indicates the company has more debt than equity and a ratio above 3 is considered high. Below 0.5 means the company has little debt and significant capacity to expand it.


Highlights and Quick Summary

  • Debt/Equity for the quarter ending June 29, 2020 was 0.01 (a -13.85% decrease compared to previous quarter)
  • Year-over-year quarterly Debt/Equity decreased by -73.83%
  • Annual Debt/Equity for 2019 was 0.01 (a Infinity% increase from previous year)
  • Annual Debt/Equity for 2018 was 0.0 (a -100.0% decrease from previous year)
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Debt/Equity of Entera Bio Ltd.

Most recent Debt/Equityof ENTX including historical data for past 10 years.

Interactive Chart of Debt/Equity of Entera Bio Ltd.

Entera Bio Ltd. Debt/Equity for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 0.01 0.01
2019 0.01 0.04 0.03 0.03 0.01
2018 0.0 0.0 0.0 0.0 0.0
2017 -0.12 -0.12

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.